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Bald heads may soon not be a sign that identifies a can-
cer patient receiving treatment. Indeed, therapies for
cancer patients are improving dramatically leading to
increased survival rates, and most are associated with a
different toxicity profile. Recently, antibody-based ther-
apy has transformed the therapeutic landscape and biol-
ogy of non-small cell lung cancer (NSCLC) and other
solid tumors. This may also reshuffle the playing cards
for an intensive care unit (ICU) admission policy due to
improved outcomes. In November 2016, the results of
the KEYNOTE-024 trial showed for the first time the
superiority of immunotherapy over chemotherapy as
first-line treatment for NSCLC [1]. In this phase 3 trial,
a humanized monoclonal antibody (mAb) against pro-
grammed death 1 (PD-1) was tested in patients who had
previously untreated advanced NSCLC. The clinical trial
was stopped by the safety monitoring committee on the
basis of substantial clinical benefit of immunotherapy,
and patients remaining in the chemotherapy group were
switched to receive immunotherapy.
Immunotherapy with immune checkpoint inhibitors
has ushered in a new chapter in the treatment of solid
tumors. In place of directly targeting cancer cells, these
drugs stimulate immune cells to enhance the host im-
mune response against cancer. Two classes of immune
checkpoint inhibitors with blocking antibodies have
demonstrated a high level of antitumor activity in a var-
iety of malignancies: (i) anti-cytotoxic T-lymphocyte
antigen-4 antibodies (not yet approved in NSCLC); and
(ii) inhibitors of PD-1 (nivolumab, atezolizumab, and
pembrolizumab)—all established second-line therapeutic
options for patients with metastatic NSCLC [2].
Antibody-based therapy in NSCLC is a therapeutic
breakthrough—the first mAb was approved only a dec-
ade ago [3]. It is difficult to predict lung cancer mortality
because new mAb therapeutic options continue to
emerge and improve survival for patients. When a clin-
ical trial is completed in lung cancer, the overall survival
may change due to innovative immunotherapy, making
previous results obsolete overnight. Indeed, the develop-
ment of immunotherapy and combinations for lung can-
cer causes triage criteria for admission into the ICU to
be in constant flux. We believe that we have entered a
time when triage criteria based on lung cancer prognosis
will be almost impossible to define for the ICU clinician.
Consequently, ICU admissions will have to be deter-
mined by high-quality consultation between the intensi-
vist and thoracic-oncologist to define prognosis and
appropriate treatment goals. Intensivists should note
that the prognosis and survival for lung cancer will be
transformed by this mAb immunotherapy revolution.
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